Chlorotrianisene Clinical Trials

Size	Price	Qty
100mg	USD 97
500mg	USD 297

Clinical Trials

Multiple clinical trials are currently evaluating interventions—including chemoembolization prior to liver transplantation, hemorrhoidal embolization, and thrombectomy systems—across conditions such as liver cancer, hepatocellular carcinoma, internal hemorrhoids, pulmonary embolism, and musculoskeletal anomalies. Encompassing Phase 2 protocols alongside non-applicable phase designs, these studies are sponsored by academic and commercial entities including Mayo Clinic, RenJi Hospital, Boston Scientific Corporation, Innova Vascular Inc., and Hebei Medical University Third Hospital. Recruitment statuses across these active and planned studies currently range from not yet recruiting to actively recruiting.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06353126	Not yet recruiting	Liver Cancer	RenJi Hospital\|Boston Scientific Corporation	2024-06-01	Phase 2
NCT06106269	Recruiting	Internal Hemorrhoid	Mayo Clinic\|Terumo Corporation	2024-06	--
NCT06041594	Not yet recruiting	Pulmonary Embolism	Innova Vascular Inc.	2024-05	Not Applicable
NCT06272656	Recruiting	Hepatocellular Carcinoma	Hebei Medical University Third Hospital	2024-04-01	--
NCT06068595	Not yet recruiting	Musculoskeletal; Anomaly	Central Hospital Nancy France\|University of Lorraine	2024-04	Not Applicable

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Chlorotrianisene product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Chlorotrianisene acts as a synthetic, non-steroidal selective estrogen receptor modulator that binds to estrogen receptors to alter downstream hormone-responsive gene expression and signal transduction. By suppressing receptor-driven cell proliferation and biological activity, this compound exerts therapeutic relevance in target conditions such as hepatocellular carcinoma and liver cancer.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).